PDCD1 and non-Hodgkin lymphoma: The highest ORR and CRR were observed in patients with T/NK-NHL (n = 15; 60% and 27%, respectively); 6 had received prior SCT, 3 had received other HDACi therapy, 4 had received programmed cell death protein-1 inhibitors, and all were refractory to their most recent therapy (supplemental Table 1); one of the CRs was achieved in a patient who never responded to HDACi.